ARMATA PHARMACEUTICALS, INC. Operating Lease, Liability, Current
ARMATA PHARMACEUTICALS, INC. (ARMP) had Operating Lease, Liability, Current of $4.62 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-08-12
- 2026-06-30: Operating Lease, Liability, Current $4.62M.
- 2026-03-31: Operating Lease, Liability, Current $4.59M.
- 2025-12-31: Operating Lease, Liability, Current $4.56M.
- 2025-09-30: Operating Lease, Liability, Current $4.53M.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-06-30 | $4.62M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $4.59M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $4.56M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $4.53M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $4.49M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $4.46M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $4.43M 10-K · filed 2026-03-25 |
| 2024-09-30 | $4.99M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $6.60M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $7.50M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $9.48M 10-K · filed 2025-03-21 |
| 2023-09-30 | $13.44M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $14.53M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $13.10M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $17.01M 10-K · filed 2024-03-21 |
| 2022-09-30 | $2.22M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.71M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $1.52M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $1.51M 10-K · filed 2023-03-16 |
| 2021-09-30 | $1.73M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $1.67M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $1.61M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $1.55M 10-K · filed 2022-03-17 |
| 2020-09-30 | $1.41M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $405.00K 10-Q · filed 2020-08-13 |
| 2020-03-31 | $1.37M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $1.31M 10-K · filed 2021-03-18 |
| 2019-09-30 | $1.25M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $1.26M 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |